Document is current
Any future updates will be listed below
-
Authors
Luozzo, Lorenzo Di
Salvato, Mariangela https://orcid.org/0009-0005-5809-6716
Frizzera, Francesca
Khalid, Kiren
Zen, Margherita https://orcid.org/0000-0003-0835-1406
Doria, Andrea https://orcid.org/0000-0003-0548-4983
Ramonda, Roberta https://orcid.org/0000-0002-9683-8873
Giollo, Alessandro https://orcid.org/0000-0001-9355-7673
-
Funding
Funding for this research was provided by:
Ministero della Salute (POS-T3_AN)
Ministero della Salute (POS-T3_AN)
- License Information
-
More Information
Article History
Received: 27 August 2025
Accepted: 4 November 2025
First Online: 19 December 2025
Declarations
:
: This study was approved by the Ethics Committee of the Central - Eastern Veneto Area (CET-ACEV) with number 6007/AO/24.
: Not applicable.
: Lorenzo Di Luozzo has no known competing financial interests or personal relationships. Mariangela Salvato has received grants from the Ministry of Health. Francesca Frizzera has no known competing financial interests or personal relationships. Kiren Khalid has no known competing financial interests or personal relationships. Margherita Zen has received consulting and speaking fees from AbbVie, Eli Lilly, GSK, Pfizer, UCB, and AstraZeneca. Andrea Doria has received travel grants, consulting and speaking fees, and advisory board fees from Eli Lilly, GSK, Pfizer, Celgene, Baxalta, and AstraZeneca. Roberta Ramonda has received travel grants, consulting and speaking fees, and advisory board fees from AbbVie, Novartis, Johnson & Johnson, Eli Lilly, MSD, Pfizer, UCB, Amgen, Celltrion, and AstraZeneca. Alessandro Giollo has received consulting and speaking fees from AbbVie, Novartis, Eli Lilly, UCB, Medac, Boehringer, and Galapagos, as well as funding from the Ministry of Health.
